Clinical Trials | December 27, 2025
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
